The DANish Acute Myocardial Infarction 2 (DANAMI-2) trial showed the 30-day superiority of patient transport to a primary angioplasty site vs. fibrinolysis at the hospital where the patient had been originally admitted. Those 30-day results became a landmark in the history of interventional cardiology. However, some suspected that such initial benefit could fade away over<a href="https://solaci.org/en/2020/03/27/16-years-of-superiority-of-primary-angioplasty/" title="Read more" >...</a>
Long after AHA 2019 had presented observational studies showing adverse events associated to Impella, JAMA is finally publishing the official results including all charts and small print. The controversial analysis of the American registry had suggested worse outcomes with the intravascular microaxial left ventricular assist device Impella vs. the intra-aortic balloon pump in acute myocardial<a href="https://solaci.org/en/2020/03/06/impella-and-adverse-events/" title="Read more" >...</a>
01- Soon after the EXCEL “Scandal” the NOBLE 5-year Outcomes Come Out: Mere Coincidence? There is no such thing as coincidence, at least not for the evidence-based medical science. This is what the NOBLE 5-year outcomes, soon to be published in the Lancet, seem to say, in line with the BBC exposé of the EXCEL<a href="https://solaci.org/en/2020/02/05/the-most-read-scientific-articles-of-january-in-solaci-org/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. In modern studies, carotid artery stenting (CAS) has been shown equal to surgery in terms of the composite end point of periprocedural stroke, death, acute myocardial infarction and late ipsilateral stroke. This was tested in different groups and by trained operators. In the CREST-2 Registry (C2R) 2141 patients were included,<a href="https://solaci.org/en/2020/01/27/crest-2-registry-carotid-pci-presents-low-rates-of-death-and-stroke/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Advanced peripheral vascular disease is frequently associated with cardiovascular events and amputation. It has been proven that mono-antiplatelet therapy (MAPT) offers some benefit (with either aspirin or clopidogrel), but there are scarce data on the role of dual antiplatelet therapy (DAPT) in these patients. Researchers analyzed 404 patients who received MAPT for<a href="https://solaci.org/en/2020/01/07/we-should-indicate-more-than-6-months-of-dapt-in-lower-limb-disease/" title="Read more" >...</a>
The European Association for Cardio-Thoracic Surgery (EACTS) formally withdrew its support for the latest coronary revascularization guidelines following a BBC investigation suggesting that data from the EXCEL trial might have been manipulated. The recommendations for left main coronary artery revascularization featured in the 2018 guidelines, which were written jointly with the European Society of Cardiology<a href="https://solaci.org/en/2020/01/06/latest-guidelines-dropped-after-scandal-over-excel-results/" title="Read more" >...</a>
Among patients in the main ISCHEMIA trial, those with chronic kidney disease are a particularly high-risk subgroup. However, an invasive strategy with coronary angiography and revascularization did not improve the rate of events, similarly to what happened in the general population for the aforementioned trial. The rate of death or acute myocardial infarction was 36.4%<a href="https://solaci.org/en/2019/11/22/aha-2019-ischemia-ckd-chronic-kidney-disease-and-stable-coronary-disease/" title="Read more" >...</a>
Courtesy of SBHCI. The COMPLETE study was carried out to assess the benefit of complete revascularization vs culprit vessel revascularization in the context of ST elevation acute myocardial infarction. This COMPLETE sub-study presented at TCT 2019 scientific sessions simultaneously published in JACC assessed the optimal timing of complete revascularization. The general study had already shown<a href="https://solaci.org/en/2019/10/01/tct-2019-complete-sub-study-to-find-out-complete-optimal-revascularization-timing-in-stemi/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. About 12% of patients >75 years old have aortic stenosis. In 3%-4% of them, such disease is severe. Transcatheter aortic valve replacement (TAVR) has already proven to be beneficial for extreme-, high-, and intermediate-risk patients. Regarding low-risk patients, we currently have different analyses; two of them are randomized and their results are<a href="https://solaci.org/en/2019/09/30/very-encouraging-results-for-tavr-in-low-risk-patients/" title="Read more" >...</a>
SOLACI continues their mission to foster the development of interventional cardiology in Latin America. In this regard, they will be part of a joint session together with the Mexican Interventional Cardiology Society at SOCIME 2019, to be held on October 10 thru 12 at Santa Fé Westin Hotel in Mexico City. The symposium will present<a href="https://solaci.org/en/2019/09/26/solaci-symposium-at-socime-congress-2019/" title="Read more" >...</a>